Читать книгу Principles of Virology - Jane Flint, S. Jane Flint - Страница 159

Naked DNA can be introduced into cultured animal cells as complexes with calcium phosphate or lipid-based reagents or directly by electroporation. Such DNA can direct synthesis of its gene products transiently or stably from integrated or episomal copies. Introduction of DNA into cells is a routine method in virological research and is also employed for certain clinical applications, such as the production of a therapeutic protein or a vaccine or the engineering of primary cells, progenitor cells, and stem cells for subsequent introduction into patients. However, this approach is not suitable for all applications. In some cases, gene delivery by viral vector is preferred. Viral vectors have also found widespread use in the research laboratory, including applications in which the delivery of a gene to specific cells, or at high efficiency, is desired. The use of viral vectors for gene therapy, the delivery of a gene to patients who either lack the gene or carry defective versions of it, or to destroy tumors typically employs viral vectors, not naked DNA (see Volume II, Chapter 9). In one application, DNA including the gene is introduced and expressed in cells obtained from the patient. After infusion into patients, the cells can become permanently established. If the primary cells to be used are limiting in a culture (e.g., stem cells), it is not practical to select and amplify the rare cells that receive naked DNA. Recombinant viruses carrying foreign genes can infect a greater percentage of cells and thus facilitate generation of the desired population. A complete understanding of the structure and function of viral vectors requires knowledge of viral genome replication, a topic discussed in subsequent chapters for selected viruses and summarized in the Appendix.

Design requirements for viral vectors include the use of an appropriate promoter, maintenance of genome size within the packaging limit of the particle, and elimination of viral virulence, the capacity of the virus to cause disease. Expression of foreign genes from viral vectors may be controlled by homologous or heterologous promoters and enhancers chosen to support efficient or cell-type-specific transcription, depending on the goals of the experiment. Such genes can be built directly into the viral genome or introduced by recombination in cells, as described above (see “Engineering Mutations into Viral Genomes”). The viral vector genome generally carries deletions and sometimes additional mutations. Deletion of some viral sequences is often required to overcome the limitations on the size of viral genomes that can be packaged in virus particles.

When viral vectors are designed for therapeutic purposes, it is essential to prevent their reproduction as well as destruction of target host cells. The deletions necessary to accommodate a foreign gene may contribute to such disabling of the vector. For example, the E1A protein-coding sequences that are always deleted from adenovirus vectors are necessary for efficient transcription of viral early genes; in their absence, viral yields from cells in culture are reduced by about 3 to 6 orders of magnitude (depending on the cell type). Removal of E1A-coding sequences from adenovirus vectors is therefore doubly beneficial, although it is not sufficient to ensure that the vector cannot reproduce or induce damage in a host animal. Adenovirus-associated virus vectors are not lytic, obviating the need for such manipulations. As discussed in detail in Volume II, Chapter 9, production of virus vectors that do not cause disease can be more difficult to achieve.

A summary of viral vectors is presented in Table 3.1, and examples are discussed below.